Menu

FEWER DOSES PER YEAR THAN ANY OTHER IL-17 INHIBITOR1-4

On this page:

Fewest Number of Doses

Device Options

Dark teal, light teal, and lime green graphic that says, “1 Dose EVERY 4 WEEKS FOR 16 WEEKS followed by 1 Dose EVERY 8 WEEKS”
1

The recommended dose of BIMZELX for adult patients with moderate-to-severe plaque psoriasis is 320 mg (given as 2 subcutaneous injections of 160 mg each) at Weeks 0, 4, 8, 12, and 16, then every 8 weeks thereafter. For patients weighing ≥ 120 kg, consider a dosage of 320mg every 4 weeks after Week 16.1


THE ONLY IL-17 WITH DOSING EVERY 8 WEEKS1-4

Dark and light teal graphic with dosing syringes indicates BIMZELX dosing schedule for initiation doses and maintenance doses
Dark and light teal graphic with dosing syringes indicates BIMZELX dosing schedule for initiation doses and maintenance doses
table
Simple dark teal dosing chart comparing year 1 doses and then yearly maintenance doses for BIMZELX, COSENTYX, TALTZ, and SILIQ.

*7 doses every other year.

IL=interleukin.

 

 

 

Image of an injection device with the word "Autoinjector" written to the lower right of the device
Image of an injection device with the word "Autoinjector" written to the lower right of the device
arrow

CONSISTENT SAFETY PROFILE ACROSS KEY CLINICAL TRIALS THROUGH 3 YEARS5

See Safety Profile

WANT MORE INFORMATION ABOUT BIMZELX?

Get updates and contact a sales representative

IMPORTANT SAFETY INFORMATION

Suicidal Ideation and Behavior

BIMZELX® (bimekizumab-bkzx) may increase the risk of suicidal ideation and behavior (SI/B). A causal association between treatment with BIMZELX and increased risk of SI/B has not been established. Prescribers should weigh the potential risks and benefits before using BIMZELX in patients with a history of severe depression or SI/B. Advise monitoring for the emergence or worsening of depression, suicidal ideation, or other mood changes. If such changes occur, advise to promptly seek medical attention, refer to a mental health professional as appropriate, and re-evaluate the risks and benefits of continuing treatment.

Infections

BIMZELX may increase the risk of infections. Do not initiate treatment with BIMZELX in patients with any clinically important active infection until the infection resolves or is adequately treated. In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing BIMZELX. Instruct patients to seek medical advice if signs or symptoms suggestive of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, monitor the patient closely and do not administer BIMZELX until the infection resolves.

Tuberculosis

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with BIMZELX. Avoid the use of BIMZELX in patients with active TB infection. Initiate treatment of latent TB prior to administering BIMZELX. Consider anti-TB therapy prior to initiation of BIMZELX in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Closely monitor patients for signs and symptoms of active TB during and after treatment.

Liver Biochemical Abnormalities

Elevated serum transaminases were reported in clinical trials with BIMZELX. Test liver enzymes, alkaline phosphatase and bilirubin at baseline, periodically during treatment with BIMZELX and according to routine patient management. If treatment-related increases in liver enzymes occur and drug-induced liver injury is suspected, interrupt BIMZELX until a diagnosis of liver injury is excluded. Permanently discontinue use of BIMZELX in patients with causally associated combined elevations of transaminases and bilirubin. Avoid use of BIMZELX in patients with acute liver disease or cirrhosis.

Inflammatory Bowel Disease

Cases of inflammatory bowel disease (IBD) have been reported in patients treated with IL-17 inhibitors, including BIMZELX. Avoid use of BIMZELX in patients with active IBD. During BIMZELX treatment, monitor patients for signs and symptoms of IBD and discontinue treatment if new onset or worsening of signs and symptoms occurs.

Immunizations

Prior to initiating therapy with BIMZELX, complete all age-appropriate vaccinations according to current immunization guidelines. Avoid the use of live vaccines in patients treated with BIMZELX.

MOST COMMON ADVERSE REACTIONS

Most common adverse reactions (≥ 1%) are upper respiratory infections, oral candidiasis, headache, injection site reactions, tinea infections, gastroenteritis, Herpes Simplex infections, acne, folliculitis, other Candida infections, and fatigue.

References:

1. BIMZELX® [prescribing information]. Smyrna, GA: UCB, Inc. 2. COSENTYX® [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp. 3. TALTZ® [prescribing information]. Indianapolis, IN: Eli Lilly and Company. 4. SILIQ® [prescribing information]. Bridgewater, NJ: Bausch Health US, LLC. 5. Data on file. UCB, Inc.; Smyrna, GA.